WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H206081
CAS#: 548486-59-5 (free base)
Description: Ulodesine, also known as BCX4208, is a purine nucleoside phosphorylase (PNP) inhibitor in development as a once-daily oral, chronic treatment for gout. Ulodesine is currently being developed by Biocryst. Ulodesine acts upstream of xanthine oxidase in the purine metabolism pathway to reduce the production of serum uric acid (sUA). Ulodesine has an IC(50) of 0.5 nM to PNP. BCX-4208 is currently undergoing early clinical investigation in psoriasis and gout.
Hodoodo Cat#: H206081
Name: Ulodesine
CAS#: 548486-59-5 (free base)
Chemical Formula: C12H16N4O3
Exact Mass: 264.12
Molecular Weight: 264.280
Elemental Analysis: C, 54.54; H, 6.10; N, 21.20; O, 18.16
Related CAS #: 1246200-39-4 (succinate) 548486-59-5 (free base)
Synonym: BCX4208, BCX 4208, BCX-4208, Ulodesine, DADMe-immucillin H
IUPAC/Chemical Name: 7-(((3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one
InChi Key: AFNHHLILYQEHKK-BDAKNGLRSA-N
InChi Code: InChI=1S/C12H16N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-9,13,17-18H,2-5H2,(H,14,15,19)/t8-,9+/m1/s1
SMILES Code: O=C1C(NC=C2CN3C[C@H](O)[C@@H](CO)C3)=C2N=CN1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | Ulodesine, also known as BCX4208, is a purine nucleoside phosphorylase (PNP) inhibitor. |
| In vitro activity: | TBD |
| In vivo activity: | TBD |
The following data is based on the product molecular weight 264.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | TBD |
| In vitro protocol: | TBD |
| In vivo protocol: | TBD |
1: Bantia S, Parker C, Upshaw R, Cunningham A, Kotian P, Kilpatrick JM, Morris P, Chand P, Babu YS. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol. 2010 Jul;10(7):784-90. doi: 10.1016/j.intimp.2010.04.009. Epub 2010 Apr 22. PubMed PMID: 20399911.
2: Kamath VP, Juarez-Brambila JJ, Morris PE Jr. Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7. doi: 10.1002/dta.24. PubMed PMID: 20355185.
